摘要
目的:评价国产异长春花碱(艾克宁)与顺铂(DDP)联合治疗老年(大于65岁)晚期非小细胞肺癌(NSCLC)患者的疗效与安全性。方法:艾克宁25mg/m2静脉注入第1、第8天,顺铂30mg/m2静脉滴注第1天~第3天,每3周~4周为1周期,治疗晚期NSCLC患者63例,A组(>65岁)33例;B组(<65岁)30例。结果:A、B两组有效率分别为45.5%(15/33)、46.7%(14/30),无显著性差异(P>0.05),主要毒性为骨髓抑制、白细胞减少Ⅲ~Ⅳ度发生率A、B两组分别为54.5%(18/33)、46.7%(14/30),无显著性差异(P>0.05),胃肠道反应发生率A、B两组分别为54.5%(18/33)、60.0%(18/30),无显著性差异(P>0.05)。结论:艾克宁与DDP联合治疗老年晚期非小细胞肺癌患者,与非老年患者有同样好的疗效与安全性。
OBJECTIVE: To evaluate the efficacy and safety of vinorelbine (VRB) in combination with cisplatin (DDP) in the treatment of elderly patients (aged over 65 years) with advanced non - small cell lung cancer (NSCLC). METHODS: A total of 63 patients with advanced NSCLC were enrolled: 33 aged over 65 years were assigned to group A, and 30 aged less than 65 years were assigned to group B. The patients were administered with NVB 25 mg/m^2 iv gtt on days 1 and 8 plus DDP 30 mg/m^2 iv gtt from the first day to the third day, with 3 - 4 weeks as 1 cycle of therapy. RESULTS : The responsive rates of group A and B were 45.5% (15/33) and 46.7% (14/30), respectively, and no significant difference were noted between the two groups (P 〉 0.05 ). Myelosuppression was the chief toxic reactions; incidences of Grade Ⅲ - Ⅳ leucopenia in group A and B were 54.5% (18/33) and 46.7% (14/30), respectively, and there was no significant differences between the two groups ( P 〉 0.05), and incidences of gastrointestinal tracts in group A and B were 54.5 % (18/ 33) and 60.0% (18/30) respectively, and there was no significant difference between the two groups (P 〉 0.05). CONCLUSION: NVB and DDP used concomitantly showed a same satisfactory efficacy and safety in elderly ( 〉 65 years) patients with advanced NSCLC as in those less than 65 years with advanced NSCLC.
出处
《中国医院用药评价与分析》
2007年第1期68-70,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
非小细胞肺癌
老年患者
异长春花碱
顺铂
non - small cell lung cancer (NSCLC)
elderly patients
vinorelbin
cisplatin